5 citations,
January 2018 in “Interdisciplinary sciences: computational life sciences” Accurate protein modeling can help develop new treatments for prostate cancer and other diseases.
24 citations,
January 1996 in “The Prostate” Finasteride is a safe and effective long-term treatment for prostate enlargement, reducing prostate volume and related symptoms.
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
The combined treatment of Finasteride and Doxazosin affects prostate tissue by reducing cell growth and altering hormone levels.
18 citations,
July 2015 in “Drug Healthcare and Patient Safety” Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.
7 citations,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
7 citations,
August 2006 in “Maturitas” Cimicifuga racemosa extract may help prevent and treat prostate issues by inhibiting 5α-reductase.
113 citations,
July 2020 in “Communications biology” Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.
11 citations,
April 2013 in “Journal of Agricultural and Food Chemistry” Monascus helps prevent baldness, prostate issues, and may be a natural alternative to medications.
7 citations,
January 1994 in “Annual Reports in Medicinal Chemistry” Understanding how androgens work is key for creating new treatments for prostate issues and hair/skin conditions.
2 citations,
January 2011 in “Andrologia” Flutamide and a new synthetic steroid affected brain and prostate chemicals and showed potential for treating androgen-related conditions and epilepsy.
1 citations,
January 2022 in “European Journal of Pharmacology” Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
6 citations,
January 1996 in “Endocrine-related Cancer” Combining flutamide and finasteride can reduce prostate weight and tumor growth, potentially benefiting treatments needing optimal DHT inhibition.
116 citations,
May 1992 in “The American Journal of Medicine” Flutamide rarely causes liver toxicity in prostate cancer patients.
52 citations,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
193 citations,
August 1985 in “Endocrinology” Different animals have unique versions of the enzyme that changes testosterone into another hormone, which is important for creating effective treatments for prostate and hair loss conditions.
121 citations,
November 2020 in “Endocrine” Male hormones like testosterone may make COVID-19 worse, and testing for sensitivity to these hormones could help predict how severe a patient's symptoms might be. Treatments that reduce these hormones are being explored.
17 citations,
August 2019 in “Archives of Cardiovascular Diseases” Low testosterone in men is a risk factor for a specific heart rhythm issue, and testosterone treatment may help prevent it.
January 2010 in “Yearbook of Endocrinology” Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
June 2007 in “Endocrinology and Metabolism Clinics of North America” The document covers various male health issues, their causes, treatments, and related conditions.
451 citations,
March 2005 in “Endocrine Reviews” The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.
30 citations,
June 1988 in “Journal of Steroid Biochemistry” Flutamide combined with an LHRH agonist effectively inhibits prostate growth, suggesting it could treat prostate cancer.
24 citations,
June 2011 in “Andrologia” Ganoderma lucidum may help treat enlarged prostate in rats.
11 citations,
September 2021 in “Journal of molecular endocrinology” ERβ has potential in treating prostate cancer and neurodegenerative diseases, but human studies are needed before clinical use.
April 2021 in “IntechOpen eBooks” Androgens, male hormones, affect physical and mental functions, with a decrease leading to health issues like muscle loss, bone disease, and depression, and more research is needed on long-term effects and treatments.
September 2010 in “European Urology Supplements” Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.
December 1998 in “Acta Crystallographica Section C-crystal Structure Communications” A new compound with strong antiandrogenic effects was found, potentially useful for treating conditions like acne and prostate cancer.
Androgen-modulating drugs do not significantly change the heat sensitivity of prostate cancer cells.
137 citations,
March 2006 in “Cns Drug Reviews” Finasteride treats enlarged prostate and hair loss, but may cause side effects in some patients.
228 citations,
February 2003 in “Urology” Androgen deprivation therapy for prostate cancer can cause sexual, physical, and psychological side effects, and doctors should manage these carefully.